Safety and efficacy of idelalisib in patient with chronic lymphocytic leukemia or lymphoma relapsing after allogeneic hematopoietic cell transplantation
Phase of Trial: Phase IV
Latest Information Update: 22 Dec 2017
At a glance
- Drugs Idelalisib (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; T cell lymphoma
- Focus Therapeutic Use
- 22 Dec 2017 As of June 22, 2017, a total of 28 patients had been registered according to results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
- 22 Dec 2017 New trial record
- 12 Dec 2017 Results (n=24) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.